Atossa Therapeutics Inc
ATOS
NASDAQ
Biotechnology
$2.60
USD
+0.04 (+1.56%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $24.95M
Volume 95.9K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-37.71M
TTM
-31.3%
YoY
Operating Cash Flow
$-35.77M
TTM
-43.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 3.5 | 3.9 | 5.3 | 5.1 | 3.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 9.0 | 9.3 | 11.4 | 9.9 | 8.7 |
Operating Income | -9.0 | -9.3 | -11.4 | -9.9 | -8.7 |
EBITDA | -9.0 | -9.2 | -11.4 | -9.9 | -8.7 |
Other Income / Expense | -0.0 | -0.0 | 0.1 | -0.0 | -0.0 |
Total Other Income / Expense | 0.6 | 0.6 | 0.5 | 0.3 | 0.2 |
Income Before Income Taxes | -8.4 | -8.7 | -10.9 | -9.6 | -8.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -8.4 | -8.7 | -10.9 | -9.6 | -8.5 |
Consolidated Net Income / Loss | -8.4 | -8.7 | -10.9 | -9.6 | -8.5 |
Net Income Attributable to Common Shareholders | -8.4 | -8.7 | -10.9 | -9.6 | -8.5 |
Basic EPS | -$0.98 | -$1.05 | -$1.27 | -$1.11 | -$0.95 |
Diluted EPS | -$0.98 | -$1.05 | -$1.27 | -$1.11 | -$0.95 |
Basic Shares Outstanding | 8.6M | 8.6M | 8.6M | 8.6M | 8.9M |
Diluted Shares Outstanding | 8.6M | 8.6M | 8.6M | 8.6M | 8.9M |